F-FDG-PET/CT) to directly assess vascular inflammation, FDG uptake was higher in RA patients than in controls. Using a substantially larger sample of RA patients, we sought to identify RA disease characteristics independently associated with vascular FDG uptake.
Methods. RA patients underwent cardiac FDG-PET/CT, with aortic inflammation assessed by quantification of FDG uptake in the ascending aorta, calculated as the mean and maximum (max) standardized uptake value (SUV) of the entire ascending aorta and of its most diseased segment (SUV MDS). Univariate and multivariable regression models were constructed to model the associations of patient characteristics with aortic FDG uptake.
Results. Ninety-one RA patients were scanned. In multivariable models, in addition to the independent associations of hypertension and body mass index with increased aortic FDG uptake, the prevalence of rheumatoid nodules correlated with the SUV mean and SUV MDS mean measures, while anti-cyclic citrullinated peptide (anti-CCP) antibodies correlated inversely with these measures and with the SUV max and SUV MDS max (P < 0.05). A significant association of RA disease activity with aortic FDG uptake was observed but was restricted to anti-CCP seropositivity.
Conclusion. Traditional CV risk factors and RA disease characteristics (rheumatoid nodules and the Disease Activity Score in 28 joints using the C-reactive protein level in anti-CCP antibody-positive individuals) were independently associated with ascending aortic FDG uptake in RA patients without clinical CVD.
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease primarily affecting the synovial joints but with important extraarticular features including significant effects on the cardiovascular (CV) system (1). Despite therapeutic advances over past decades, CV disease (CVD) continues to be the leading cause of excess deaths in RA, with CVD mortality rates 1.5-3-fold higher than those in matched controls (2) . Unfortunately, CV risk algorithms established for the general population generally underperform in RA (3); therefore, the development of strategies to better identify and manage the increased CV risk in RA has become a priority.
Chronic systemic and/or vascular inflammation is believed to contribute to the excess risk of atherosclerosis and CV events in RA. Atherosclerosis is an inflammatory process reflected in plaque by infiltrating macrophages and T cells, and reflected systemically by mildly elevated levels of inflammatory cytokines (such as tumor necrosis factor [TNF] , interleukin-1 , and IL-6) and matrix metalloproteinases (MMPs) (4, 5) . Mild elevations of these cytokines and MMPs are potent predictors of CV events in the general population, presumably through their promotion of plaque rupture (6) (7) (8) . RA is characterized by much higher serum levels of the same molecules (5) , which has led to the hypothesis that this amplified systemic inflammatory milieu accelerates atherosclerosis and plaque rupture in patients with RA. Indeed, a number of studies have shown circulating and articular measures of inflammation to be independent predictors of CV events in RA (9) (10) (11) . However, an alternate or complementary hypothesis is that vascular inflammation is also enhanced in RA patients relative to non-RA controls, but direct assessments of this hypothesis are few and consist of small sample sizes (12) (13) (14) .
Most assessments of atherosclerosis in RA to date have used imaging techniques that identify the presence of atherosclerotic plaque and luminal stenosis, but not arterial wall inflammation. This is a crucial limitation, as plaque inflammation is believed to represent one of the early and reversible steps of atherosclerosis (15, 16) . In addition, although assumed to occur rarely, rheumatoid aortitis has been described in the spectrum of rheumatoid vasculitis independent of atherosclerotic plaque (17) (18) (19) . The recent development of techniques that enable coregistration of positron emission tomography (PET) with computed tomography (CT) (or magnetic resonance imaging [MRI] ) scans coupled with radioisotopes that are avidly taken up by macrophages (i.e., fluorodeoxyglucose [FDG] ) has enabled the direct identification of inflammation in vascular walls, providing not only morphologic but also physiologic information. Importantly, increased FDG uptake in the vessel wall suggests plaque instability, a risk factor for plaque rupture and CV events, but it may also represent vasculitis (20, 21) . Although identification of vascular inflammation in the coronary arteries is ultimately preferred, PET imaging of the coronary arteries remains challenging due to their small caliber as well as their motion during cardiac cycles (22) . However, the known association of aortic atherosclerosis, as well as aortic FDG uptake, with CV events in the general population (20, 21) makes the study of aortic inflammation of particular interest in RA.
Although vascular FDG-PET/CT studies in RA are few, Maki-Petaja et al reported a level of aortic FDG uptake in 17 RA patients with high disease activity equivalent to that of 34 non-RA subjects with stable coronary artery disease (12) . A cross-sectional study of 10 psoriasis patients and 5 RA patients also demonstrated higher aortic FDG uptake compared with 10 healthy subjects after adjustment for CV risk factors (13) . However, the small RA sample sizes in these studies were inadequate to identify RA-specific factors associated with vascular inflammation. In this crosssectional study, we hypothesized that RA-specific features would be associated with ascending aortic FDG uptake independent of conventional CV risk factors.
PATIENTS AND METHODS
Patients. The first 91 RA patients enrolled in the Rheumatoid arthritis study of the Myocardium (RHYTHM) between November 2011 and March 2015 constituted the study population. RHYTHM is an ongoing study to identify and evaluate factors associated with subclinical myocardial phenotypes in RA patients without clinical CVD. Eligibility for the RA patients required fulfillment of the American College of Rheumatology/ European League Against Rheumatism 2010 classification criteria (23) and age ≥18 years. Participants with a history of clinical CVD, defined as a self-reported physician-diagnosed myocardial infarction, heart failure, coronary artery revascularization, angioplasty, peripheral arterial disease, or procedures, pacemaker, or defibrillator devices, or stroke or transient ischemic attack, were excluded from participation. Additional exclusion criteria included contraindications to receiving a vasodilator (adenosine or regadenoson) and an active history of cancer. Patients were consecutively recruited from the Columbia University Rheumatology Clinics and from local referring rheumatologists. All participants provided written consent prior to participation. The study was in compliance with the Declaration of Helsinki and approved by the Columbia University Institutional Review Board. Enrollment for RHYTHM began in 2011 and is ongoing.
Outcome measures. Ascending aortic 18 F-FDG-PET/CT uptake. FDG-PET/CT imaging of the ascending aorta was performed using reproducible, validated methods (24, 25) . Specifically, 10 mCi 18 F-FDG was administered intravenously after 18 hours of a carbohydrate-free diet (in order to suppress myocardial FDG uptake) and an overnight fast. All patients had a blood sugar concentration of <200 mg/dl at the time of imaging. Imaging was performed 90 minutes after FDG injection. A CT scan was obtained for attenuation correction and anatomic coregistration, using a voltage of 120 kVp and mAs of 25. Thereafter, PET imaging of the chest was performed, with 10 minutes per bed position. The pitch was 2.8 and slice thickness was 3.27 mm. Reconstruction of attenuation-corrected images was done using the ordered-subsets expectation-maximization algorithm with corrections for normalization, dead time, random events, scatter, attenuation, and sensitivity. Analyses were restricted to the ascending aorta, since the CT scan performed for coregistration was a cardiac CT which did not include the upper chest or neck. The area of interest was defined as the region of the aorta beginning 1 cm above the origin of the left main coronary artery and ending at the aortic arch in transaxial view.
Ascending aortic inflammation was determined by 18 F-FDG-PET uptake in the arterial wall, calculated as the standardized uptake value (SUV): SUV = r/(a 0 /w), where r is the radioactivity concentration (kBq/ml) measured by the PET scanner within a region of interest (ROI), a 0 is the decay-corrected amount of injected radiolabeled FDG (kBq), and w is the weight of the patient (gm), which is used as a surrogate for a distribution volume of tracer. ROIs were drawn around the artery in transaxial orientation to measure the SUV for each ROI. We used several metrics to report the measured SUV. The SUV mean was defined as the average SUV of the entire ascending aorta (as defined above). Since each slice has a mean and a maximum value, we calculated the average of the mean values (SUV mean) and of the maximum values (SUV max) for all slices. The SUV of the most diseased segment (SUV MDS) was also assessed, defined as the average SUV max (SUV MDS max) or the average MDS mean (SUV MDS mean) for 3 consecutive slices centered on the aortic slice with the highest SUV and the adjacent slice superior and inferior to it, providing~1 cm of the most inflamed section of the aortic wall. Each study was read by 2 experienced readers (RW and SB) using a Medview display integrated into Corridor 4DM software, version 7.0 (Invia Medical Imaging Solutions) (26) . Interreader correlation for the SUV measurements was 0.997.
Coronary artery calcification (CAC). CAC was ascertained with cardiac CT using a multidetector row CT system and quantified by the Agatston method (27) .
Clinical covariates. Information on demographics and smoking was collected using standardized health questionnaires. Resting blood pressure (BP) was measured 3 times, and the mean value of the last 2 measurements was used in the analyses. Hypertension was defined as a systolic BP of ≥140 mm Hg, a diastolic BP of ≥90 mm Hg, or use of antihypertensive medication. Diabetes mellitus was defined as a fasting serum glucose level of ≥126 mg/dl or use of antidiabetic medication. Body mass index (BMI) was calculated as weight (in kg) divided by height (in m 2 ). Prescription and over-the-counter medications taken within the preceding 2 weeks were documented from containers supplied by participants. RA disease duration was calculated from the date of physician diagnosis. RA activity was calculated using the Disease Activity Score in 28 joints (28) using the Creactive protein level (DAS28-CRP) (29) . Current and past use of glucocorticoids and of biologic and nonbiologic disease-modifying antirheumatic drugs (DMARDs) was ascertained by patient interview and medical records. Nonbiologic DMARDs included methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide. Biologic DMARDs included adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab, abatacept, tofacitinib, anakinra, and rituximab.
Laboratory covariates. Phlebotomy was performed after an overnight fast at the same visit as the FDG-PET/CT visit. Serum and plasma were separated by centrifugation and stored at -80°C. All analytes were measured in the Biomarkers Core Laboratory of the Columbia University Irving Institute for Clinical and Translation Research. Anti-cyclic citrullinated peptide (anti-CCP) antibodies were assessed by enzyme-linked immunosorbent assay (ELISA) using a Quanta Lite CCP3 IgG kit (Inova Diagnostics) with positivity defined as ≥60 units/ml. Total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were measured in plasma by colorimetric assay using Cobas Integra 400 Plus kits (Roche Diagnostics), and low-density lipoprotein cholesterol was calculated using the Friedewald formula. IL-6 was assayed by ELISA test kits (R&D Systems). High-sensitivity CRP was measured by turbidimetric immunoassay from Cobas Integra 400 Plus kits. IgM rheumatoid factor (RF) antibodies were assessed by ELISA, with RF positivity defined as a concentration of ≥40 units/ml.
Statistical analysis. The analyses in this report were not conceived in the original design of the RHYTHM study, which focused on myocardial FDG uptake; rather, they were performed as post hoc analyses, hence with no a priori hypothesis or power calculation to test the aortic FDG uptake. However, the question of interest was whether RA-specific characteristics would identify patients with higher aortic FDG uptake, independent of conventional CV risk factors. Because uptake could conceivably represent discrete (or diffuse) atherosclerotic plaque or diffuse vasculitic involvement, we explored as our primary outcome several measures of FDG uptake (SUV mean, SUV max, SUV MDS mean, and SUV MDS max).
The normality of the variables of interest was determined by graphic assessment and the Kolmogorov-Smirnov test. Summary statistics for outcomes and predictor variables were examined, with comparisons made using Student's t-test and the Wilcoxon rank sum test for normally and non-normally distributed continuous variables, respectively. Counts and percentages were calculated for categorical variables and compared using a chi-square test or Fisher's exact test, as appropriate. Linear regression models were constructed to explore the * Except where indicated otherwise, values are the number (%). RA = rheumatoid arthritis; IQR = interquartile range; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide; DAS28-CRP = Disease Activity Score in 28 joints using the C-reactive protein level; IL-6 = interleukin-6; HAQ = Health Assessment Questionnaire; DMARD = disease-modifying antirheumatic drug; CV = cardiovascular; BMI = body mass index; LDL = low-density lipoprotein; HDL = high-density lipoprotein; CAC = coronary artery calcification; SUV = standardized uptake value; max = maximum; MDS = most diseased segment. F-FDG uptake quantified as the log-transformed SUV mean, SUV max, SUV MDS mean, and SUV MDS max. Tolerance was calculated to ensure that variables with excessive collinearity were not comodeled; none of the variables had a tolerance <0.1. To isolate the association between CV risk factors and RA disease characteristics with the measures of ascending aortic FDG uptake, confounders were defined as those variables associated with both the outcome (ascending aortic FDG uptake) and the independent variables (CV risk factors and RA disease characteristics). All statistical calculations were performed using Stata software, version 12 (StataCorp) and SAS software, version 9.4 (SAS Institute). In all tests, a 2-sided alpha level of 0.05 was considered significant.
RESULTS
Patient characteristics. The characteristics of the study participants are summarized in Table 1 . Most patients (80%) were women with established disease (median RA duration 7.2 years); however, 25% had disease duration of <1.6 years. The majority (65%) were seropositive for RF and/or anti-CCP, and 8% had rheumatoid nodules. Seventy-six percent were treated with a nonbiologic DMARD and 40% with a biologic DMARD, and onethird were currently receiving prednisone at a median daily dose of 5 mg. Forty-two percent had hypertension, and 43% were current or ever smokers; only 9% had diabetes mellitus, 18% were taking statins, and one-third had a CAC score >0, and the median CAC score of those with a CAC score >0 was 130 (interquartile range 28-573). When patients were analyzed by anti-CCP antibody status, the only differences identified were higher percentages of RF and shared epitope positivity in the anti-CCP-positive group (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40345/abstract). Figure 1 shows an example of high FDG uptake in a patient compared to low FDG uptake in another patient. For the total group of RA patients, the median ascending aortic SUV mean, SUV max, SUV MDS mean, and SUV MDS max values were 1.83, 2.43, 1.91, and 2.59, respectively (Table 1) .
Univariate analysis of the association of patient characteristics with ascending aortic 18 F-FDG uptake. In univariate analysis (Table 2 ; also see Supplementary Table 2 , http://onlinelibrary.wiley.com/doi/10.1002/art.40345/abstract), age, BMI, hypertension, and CAC score were positively associated with the 4 study measures of ascending aortic FDG uptake (SUV mean, SUV max, SUV MDS mean, and SUV MDS max), while HDL cholesterol levels were negatively associated with these outcome measures. Among RA characteristics, rheumatoid nodules were positively associated with SUV mean and SUV MDS mean.
Multivariable analysis of the association of patient characteristics with ascending aortic 18 F-FDG uptake. In multivariable analyses (Table 3) , BMI remained significantly associated with all 4 measures of ascending aortic FDG uptake. In addition, the association of hypertension Radiotracer uptake in the aorta is diffuse (arrows), with a maximum standardized uptake value (SUV max) of 2.81 and an SUV max of the most diseased segment (SUV MDS max) of 2.91 for high 18 F-FDG uptake compared with an SUV max of 1.11 and an SUV MDS max of 1.16 for low 18 F-FDG uptake. 18 with SUV mean and SUV MDS mean persisted, as well as the association of age with SUV MDS max (Table 3) . Although the association of anti-CCP antibody titer ≥60 units/ml with SUV ascending aortic measures did not reach statistical significance in univariate analysis, in adjusted models the association of anti-CCP antibody titer ≥60 units/ml with all 4 measures of ascending aortic FDG uptake was statistically significant (Figure 2A) . Interestingly, the association of RA disease activity (measured by the DAS28-CRP) with ascending aortic FDG uptake varied depending on anti-CCP antibody status (P for interaction = 0.047); in those with anti-CCP antibody titer ≥60 units/ml, the higher was the DAS28-CRP, the higher were the SUV mean ( Figure 2B ) and SUV MDS mean. In addition, the association of rheumatoid nodules with SUV mean and SUV MDS mean observed in univariate analysis remained significant in the adjusted analyses (Figure 3) . No association of the shared epitope with ascending aortic FDG uptake measures was identified.
DISCUSSION
The key finding in this study is that several RAspecific features (anti-CCP seropositivity and rheumatoid nodules) are associated with ascending aortic inflammation, as measured by 18 F-FDG-PET/CT, independent of conventional CV risk factors. Additionally, we have shown that the association between RA disease activity and ascending aortic inflammation was restricted to patients with anti-CCP seropositivity. Finally, this study supports the ability of PET imaging as a tool to detect aortic vessel wall inflammation in RA patients without clinical CVD; our study is the largest study to date to investigate this vascular outcome in RA using this imaging modality.
CV disease continues to be the leading cause of death in RA patients. The excess risk compared with controls is only partially explained by traditional CV risk factors, with RA itself being independently associated with CVD (30) . Inflammation is known to play an important role in all phases of atherosclerosis, from initiation to atherothrombosis (15, 16) . Chronically higher levels of circulating inflammatory cytokines in RA patients, relative to non-RA patients with atherosclerosis, may fuel plaque inflammation and rupture leading to increased risk of CV events; however, infiltration of plaque itself with increased numbers of inflammatory cells is hypothesized to play a key role in this increased risk. A novel imaging modality, 18 F-FDG-PET, has emerged in the last decade as a marker of atherosclerosis in the general population as it allows the quantification of 18 F-FDG uptake (vascular inflammation) within the atheroma and overall in the arterial wall (24, 31) . SUVs, the outcome variables in our study, are a measure of radiotracer uptake normalized for injected dose and patient weight. SUVs are most commonly used in the assessment of 18 F-FDG-PET/CT oncology studies for the diagnosis and staging of cancer. In addition to the anatomic imaging that CT and MRI offer, multimodal imaging with FDG-PET/CT provides molecular and functional data allowing the detection of signature pathologic mechanisms.
More recently, FDG-PET/CT has been used in cardiac imaging for the diagnosis and follow-up of patients with inflammatory conditions of the heart including sarcoidosis, endocarditis, and pacemaker infections. In vivo measures of FDG-PET uptake are reproducible, correlate positively with metabolically active macrophages and macrophage infiltration into the vessel wall, and are modifiable by different pharmacologic interventions targeted at reducing atherosclerotic inflammation, such as statins (32) (33) (34) (35) . More importantly, increased arterial FDG uptake is known to predict plaque expansion and rupture, leading to CV events including myocardial infarction and GERALDINO-PARDILLA ET AL stroke (20, 21) . FDG-PET/CT is increasingly used as a primary outcome measure in randomized controlled trials of antiatherogenic drugs because arterial inflammation is believed to represent one of the early and reversible steps of atherosclerosis (36, 37) . Several studies have also shown an association between FDG signal and CV risk factors or risk scores (21, (38) (39) (40) (41) . Moreover, vascular FDG-PET imaging has been shown to improve the prediction of CVD beyond the traditionally used Framingham risk stratification score (42) . All of these features make the use of FDG-PET vascular imaging compelling in the study of CVD in RA, an illness in which systemic and articular inflammation are the sine qua non. Aortic FDG-PET imaging in 2 previous small studies of RA patients without clinical CVD revealed significantly increased subclinical aortic FDG uptake compared with that in controls (12, 13) . Rose et al (13) reported an SUV mean of 1.49 in RA patients; similarly, we identified an ascending aortic SUV mean of 1.83 in our RA cohort. In the general population it is documented that vessel wall inflammation leads to endothelial dysfunction, aortic stiffening, accelerated atherosclerosis, plaque destabilization, and adverse CV events (20, 21, 38) . Indeed, Maki-Petaja et al (12) showed in a study of 17 RA patients that a decrease in aortic stiffness in response to anti-TNF treatment was paralleled by a decrease in aortic FDG uptake. Additionally, in a study of 23 RA patients, Bernelot Moens et al showed that RA patients with long-term clinical remission of disease did not have increased arterial wall inflammation compared to controls. However, those receiving TNF inhibitors had increased aortic uptake compared to subjects receiving nonbiologic DMARDs, an association explained by longer RA disease duration (43) . Hence, identification of vessel wall inflammation in RA may detect those patients at highest risk of plaque instability/rupture and CV events.
It is also possible in RA that aortic wall inflammation could represent rheumatoid vasculitis (aortitis), which the FDG-PET/CT technology would not be able to differentiate from plaque inflammation. The prevalence of aortitis in RA had been considered low based on autopsy studies from the 1970s and 1980s (17, 18) , but the challenges in diagnosing aortitis preclude establishing its true prevalence. Thus, while most studies of vascular FDG uptake use the SUV max (33, 34) as the primary outcome measure because of their focus on atherosclerotic plaque, we also explored the SUV mean for both the MDS and the whole ascending aorta as potential outcomes that might be more reflective of diffuse homogeneous inflammation as might be envisioned with vasculitis. We speculated that conventional CV risk factors might be related to the 4 measures of FDG uptake differently from RAspecific characteristics. However, this did not appear to be the case, as a conventional CV risk factor (BMI) and an RA-specific characteristic (anti-CCP titer ≥60 units/ml) were both independently associated with all 4 measures of aortic FDG uptake. Likewise, another CV risk factor (hypertension) and another RA-specific characteristic (nodules) were both independently associated with SUV mean and SUV MDS mean but not with SUV max or SUV MDS max. It should be noted, however, that SUV max has been reported to have significantly improved reproducibility as compared to SUV mean since the SUV max value within an ROI is typically invariant with respect to small spatial shifts of the ROI, while the SUV mean is only accurate if the lesion of interest has a uniform true SUV value (44) .
That a component of ascending aortic FDG uptake in our RA patients is due to plaque is suggested by the independent association of BMI and hypertension with aortic FDG uptake; moreover, this association is consistent with reports in the general population in which arterial FDG uptake correlated with burden of CV risk factors (41) . In non-RA patients, aortic FDG uptake has also been associated with baseline CAC as well as its progression (36, 45) ; however, in our RA patients, the association of CAC with ascending aortic FDG uptake lost statistical significance in the adjusted analysis, which could have been due to the exclusion of patients with clinical CVD in our studies, in whom the median overall CAC score was zero.
Interestingly, among the RA-specific characteristics examined, we found a positive correlation between rheumatoid nodules and FDG uptake even after adjustment for CV risk factors. Surprisingly, in univariate analyses we observed a negative correlation between anti-CCP antibody status and ascending aortic FDG-PET uptake. This apparent counterintuitive association was explained, at least in part, in the multivariable analyses by an interaction with disease activity. Thus, in patients with active disease, anti-CCP seropositivity was positively associated with FDG uptake. Interestingly, citrullinated proteins have been demonstrated within aortic atherosclerotic plaque of autopsied non-RA patients, and anti-citrullinated protein antibodies (ACPAs) in RA patients have been associated with an increase in aortic plaque burden (46) , suggesting a role for ACPAs in the acceleration of atherosclerosis in RA.
Several groups have shown that statin therapy in non-RA patients results in a significant reduction in arterial FDG-PET uptake after 3 months (32) (33) (34) . In ankylosing spondylitis, similar results were seen in a small study evaluating the change in aortic FDG uptake following treatment with atorvastatin (35) . However, we did not find an association between the use of statins and aortic FDG uptake in our cross-sectional study, possibly due to the fact that only 16 of the patients in our cohort were receiving statins. Additionally, a reduction in aortic FDG uptake has been described in a small study of 17 RA patients following 8-week treatment with anti-TNF (12) . Although in another study the use of TNF blockers in 13 RA patients was associated with increased arterial uptake compared to 10 RA patients receiving nonbiologic DMARDs, the association was confounded by RA disease duration (43) . However, we did not see an association between the use of TNF inhibitors and the extent of ascending aortic FDG uptake in our cross-sectional study. An interesting question is whether any RA therapy that can induce disease remission will also reduce vascular inflammation. To address this question, the Treatments Against RA and Effect on FDG-PET/CT (TARGET) trial (ClinicalTrials.gov identifier: NCT0237402) will evaluate the effect of 2 different DMARD regimens (anti-TNF plus methotrexate versus triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine) on aortic and carotid inflammation and will correlate these findings with changes in RA disease activity (https://clinicaltrials.gov/ct2/show/NCT02374021?term= TARGET+RA&rank=1). Strengths of our study include the comprehensive phenotyping of the RA cohort for CV and RA characteristics, including both structural and physiologic measures of atherosclerosis. This, coupled with our large sample size, allowed us to evaluate for the first time the independent contributions of conventional CV risk factors and diseasespecific characteristics to increased ascending aortic FDG uptake in patients with RA.
Limitations of our study include its crosssectional nature, which precludes establishment of causation for our findings and the evaluation of whether changes in the ascending aortic FDG uptake might parallel changes in RA disease features (i.e., disease activity, markers of inflammation, treatment modifications). Also, while the consistency in the covariates retained in our final models across the different SUV measures makes our findings less likely to be due to chance, our results should be interpreted with caution.
In conclusion, in addition to conventional CV risk factors, ascending aortic FDG uptake in RA was associated with the presence of rheumatoid nodules and disease activity in those with anti-CCP antibody seropositivity. Our study results suggest that both traditional CV risk factors and RA disease characteristics are independently associated with ascending aortic wall inflammation and likely the development of atherosclerosis in RA. These findings support the use of FDG-PET imaging as an additional research modality for assessing CV risk in RA patients.
